Currently out of the existing stock ratings of Kalpit Patel, 68 are a BUY (73.12%), 25 are a HOLD (26.88%).

Kalpit Patel

Work Performance Price Targets & Ratings Chart

Analyst Kalpit Patel, currently employed at B. RILEY, carries an average stock price target met ratio of 34.77% that have a potential upside of 65.15% achieved within 138 days.

Kalpit Patel’s has documented 184 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RIGL, Rigel Pharmaceuticals at 06-Mar-2025.

Wall Street Analyst Kalpit Patel

Analyst best performing recommendations are on GERN (GERON).
The best stock recommendation documented was for GERN (GERON) at 2/27/2025. The price target of $2 was fulfilled within 1 day with a profit of $0.37 (15.61%) receiving and performance score of 156.12.

Average potential price target upside

of $9.73 (50.96%) on LBPH (LONGBOARD PHARMACEUTICALS).
of $8.47 (22.05%) on MRTX (MIRATI THER).
of $6.95 (50.38%) on VRDN (VIRIDIAN THERAPEUTICS).

BCYC Bicycle Therapeutics Ltd INFI Infinity Pharmaceuticals INKT Mink Therapeutics KYMR Kymera Therapeutics MGTA Magenta Therapeutics RIGL Rigel Pharmaceuticals FBRX Forte Biosciences ALLO Allogene Therapeutics ENTX Entera Bio Ltd INAB In8bio VINC Vincerx Pharma MRTX Mirati Ther DERM Journey Medical Corp GERN Geron VRDN Viridian Therapeutics SNDX Syndax Pharmaceuticals LBPH Longboard Pharmaceuticals CRBP Corbus Pharmaceuticals PDSB PDS Biotechnology Corp VSTM Verastem

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ami Fadia (NEEDHAM)